Where is the cancer R&D revolution headed?<\/h3>\n
Join Endpoints and the Cancer Research Institute for a panel discussion with oncology newsmakers. <\/p>\n
Over the past five years oncology research has exploded, with fast-paced development schedules delivering breakthrough drugs that are changing the standard of care. But along the way, a bubble has developed, with companies pursuing hundreds of new studies and grabbing pipeline assets in a rush to multiply checkpoint drugs and compete with therapies already on the market. Endpoints News <\/em>Editor John Carroll will review some startling new data on the cancer pipeline and lead a discussion on how this revolution can best be managed — to the advantage of patients, physicians and the biopharma companies leading the boom. <\/p>\n
CRI's Chief Medical Officer, Aiman Shalabi, is a panelist.<\/p>\n
The event will take place at Hilton Union Square, 333 O'Farrell St, San Francisco, CA 94102.<\/p>\n